The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial

被引：0
|
作者：
Browne, Iseult
Pascual, Javier
Cutts, Rosalind
Kingston, Belinda
Hrebien, Sarah
Kilburn, Lucy
Pearson, Alex
Moretti, Laura
Wardley, Andrew
Macpherson, Iain
Baird, Richard
Roylance, Rebecca
Faull, Iris
Banks, Kimberly C.
Garcia-Murillas, Isaac
Bliss, Judith
Ring, Alistair
Turner, Nicholas
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS06-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS06-04
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Androgen receptor (AR) expression in triple negative breast cancer (TNBC): results from a phase II neoadjuvant trial with carboplatin and eribulin mesylate in TNBC patients
    Siziopikou, K.
    Parini, V.
    Kaklamani, V.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 14 - 14
  • [22] Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
    Taieb, J.
    Taly, V.
    Vernerey, D.
    Bourreau, C.
    Bennouna, J.
    Faroux, R.
    Desrame, J.
    Bouche, O.
    Borg, C.
    Egreteau, J.
    Mineur, L.
    Lepere, C.
    Deplanque, G.
    Mulot, C.
    Louvet, C.
    Mabro, M.
    Ychou, M.
    de Gramont, A.
    Andre, T.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2019, 30 : 867 - 867
  • [23] Circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) predictive value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: Results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study
    Pierga, J-Y
    Silveira, A.
    Lorgis, V.
    Tanguy, M-L
    Tredan, O.
    Dubot, C.
    Jacot, W.
    Goncalves, A.
    Debled, M.
    Levy, C.
    Ferrero, J-M
    Jouannaud, C.
    Luporsi, E.
    Mouret-Reynier, M-A
    Dalenc, F.
    Lemonnier, J.
    Berger, F.
    Proudon, C.
    Bidard, F-C
    CANCER RESEARCH, 2019, 79 (04)
  • [24] A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The analyses of efficacy and safety from phase II.
    Takahashi, Masato
    Yonemori, Kan
    Yamamoto, Harukaze
    Watanabe, Ken-ichi
    Shimizu, Chikako
    Yasojima, Hiroyuki
    Masuda, Norikazu
    Takashima, Seiki
    Aogi, Kenjiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Shimizu, Satoru
    Yamamoto, Naohito
    Nakamura, Rikiya
    Michimae, Hirofumi
    Hamada, Akinobu
    Tamura, Kenji
    Fujiwara, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
    Lin, A. Y.
    Isaeva, O. I.
    Vessies, D.
    Deger, T.
    Voorwerk, L.
    Geurts, V.
    Horlings, H.
    Martens, J.
    Wessels, L.
    Van den Broek, D.
    Kok, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S380 - S380
  • [26] Efficacy and safety of olaparib combined with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The final analysis of a Japanese phase I/II trial
    Aogi, K.
    Yonemori, K.
    Takahashi, M.
    Masuda, N.
    Naito, Y.
    Shimizu, S.
    Nakamura, R.
    Yamamoto, H.
    Hamada, A.
    Michimae, H.
    Tamura, K.
    Sukigara, T.
    Nagasaka, R.
    Fujiwara, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158
    Radovich, Milan
    Jiang, Guanglong
    Chitambar, Christopher
    Nanda, Rita
    Falkson, Carla
    Lynce, Filipa C.
    Gallagher, Christopher
    Isaacs, Claudine
    Blaya, Marcelo
    Paplomata, Elisavet
    Walling, Radhika
    Daily, Karen
    Mahtani, Reshma
    Thompson, Michael A.
    Graham, Robert
    Cooper, Maureen E.
    Pavlick, Dean C.
    Albacker, Lee
    Gregg, Jeff
    Bales, Casey L.
    Hancock, Bradley A.
    Cantor, Erica
    Shen, Fei
    Storniolo, Anna Maria V.
    Badve, Sunil
    Ballinger, Tarah
    Miller, Kathy D.
    Schneider, Bryan P.
    CANCER RESEARCH, 2020, 80 (04)
  • [28] Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients
    Fettke, Heidi
    Kwan, Edmond M.
    Yu, Jianjun
    Wang, Amy
    Montesinos, Carlos
    Wong, Calvin
    Gong, Xue
    Zheng, Tiantian
    Du, Peter Pan
    Jia, Shidong
    Mant, Andrew
    Parente, Phillip
    Pezaro, Carmel
    Azad, Arun A.
    CANCER RESEARCH, 2019, 79 (13)
  • [29] Mutational analysis of circulating tumour DNA (ctDNA) in patients with ER+/HER2-advanced breast cancer (ABC) receiving palbociclib (P): Results from the TREnd trial
    Malorni, L.
    Romagnoli, D.
    Benelli, M.
    Galardi, F.
    Biagioni, C.
    Curigliano, G.
    Minisini, A. M.
    Moretti, E.
    Risi, E.
    De Luca, F.
    McCartney, A.
    Di Leo, A.
    Biganzoli, L.
    Migliaccio, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S24 - S24
  • [30] Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis
    Telli, M. L.
    McMillan, A.
    Ford, J. M.
    Richardson, A. L.
    Silver, D. P.
    Isakoff, S. J.
    Kaklamani, V. G.
    Gradishar, W.
    Stearns, V.
    Connolly, R. M.
    Loibl, S.
    Elkin, E. P.
    Timms, K.
    Hartman, A-R
    von Minckwitz, G.
    CANCER RESEARCH, 2016, 76
12345